---
title: "bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295277558.md"
description: "bioAffinity Technologies reported Q2 2026 revenue of $1.51M, a 19% YoY increase, while narrowing its net loss to $3.37M and reporting diluted EPS of $(0.64). Key highlights include a 156% rise in CyPath Lung revenue, a 122% expansion in ordering physicians, and the opening of 11 trial sites for longitudinal studies. The company also advanced diagnostics and siRNA therapeutics with positive preclinical results."
datetime: "2026-08-07T20:51:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295277558.md)
  - [en](https://longbridge.com/en/news/295277558.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295277558.md)
generator: "portal-rs"
---

# bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary

bioAffinity Technologies, Inc. reported second-quarter 2026 results with revenue of $1.51M, a 19% increase versus the year‑ago quarter, while the company narrowed its net loss to $3.37M and reported diluted loss per share of $(0.64).

**Financial Highlights**

-   Revenue: $1.51M for Q2 2026, up from $1.27M in the year‑ago quarter (19% YoY).
-   Net income: Net loss of $3.37M for Q2 2026, improved from a net loss of $4.06M in the year‑ago quarter.
-   Diluted EPS: $(0.64) per share for Q2 2026, versus $(5.07) per share in the year‑ago quarter.

**Business Highlights**

-   CyPath® Lung momentum: Year-to-date CyPath Lung revenue rose about 156%, and unit sales increased 216% in Q2, reflecting accelerating physician adoption.
-   Channel shift: The acquisition of Village Oaks and transition to in-house PPLS lab operations enabled direct commercialization of testing.
-   Market traction: Ordering physicians expanded 122% in Q2; more than 1,200 tests had been reported by July, alongside a published clinical white paper.
-   Clinical and pipeline progress: Opened 11 trial sites (including nine VA/military locations) for a longitudinal trial started March 2026 with patient enrollment underway; advancing diagnostics for lung inflammation and topical siRNA therapeutics with positive preclinical and early results.

Original SEC Filing: bioAffinity Technologies, Inc. \[ BIAF \] - 10-Q - Aug. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BIAF.US](https://longbridge.com/en/quote/BIAF.US.md)
- [BIAFW.US](https://longbridge.com/en/quote/BIAFW.US.md)

## Related News & Research

- [bioAffinity Technologies effects 1-for-15 reverse stock split effective Aug. 24, 2026](https://longbridge.com/en/news/296486716.md)
- [bioAffinity Technologies Inc trading halted, news pending](https://longbridge.com/en/news/296671624.md)
- [bioAffinity signs AvMEDICAL distribution deal for CyPath Lung in federal healthcare market](https://longbridge.com/en/news/296224749.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [SiranBio raises nearly CNY 400 million in Pre-A, A and A+ rounds, Suzhou Angel Guidance Fund says](https://longbridge.com/en/news/296444537.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**